EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 33 / No 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 905-908 References
Free Access
Issue
Med Sci (Paris)
Volume 33, Number 10, Octobre 2017
Page(s) 905 - 908
Section Forum
DOI https://doi.org/10.1051/medsci/20173310024
Published online 10 October 2017
  1. Van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415 : 530–536. [CrossRef] [PubMed] [Google Scholar]
  2. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817–2826. [Google Scholar]
  3. Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375 : 717–729. [Google Scholar]
  4. Shen T, Pajaro-Van de Stadt SH, Yeat NC, Lin JC. Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front Genet 2015; 6 : 215. [CrossRef] [PubMed] [Google Scholar]
  5. Jordan B. Recherche cibles, désespérément. Med Sci (Paris) 2015 ; 31 : 214–217. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Massard C, Michiels S, Ferté C, Le Deley MC, et al. high-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 Trial. Cancer Discov 2017 ; 7 : 586–595. [CrossRef] [PubMed] [Google Scholar]
  7. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017 ; 14 : 381–390. [PubMed] [Google Scholar]
  8. Champiat S, Soria JC. Nouvelles pratiques en immuno-oncologie : une révolution et un immense défi scientifique et médical. Med Sci (Paris) 2017 ; 33 : 563–564. [Google Scholar]
  9. Teillaud JL. Quand les anticorps rencontrent l’immunité antitumorale : fin de partie pour la cellule cancéreuse ?. Med Sci (Paris) 2015 ; 31 : 707–708. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Calling time on the immunotherapy gold rush (Editorial). Lancet Oncol 2017 ; 18 : 981. [CrossRef] [PubMed] [Google Scholar]
  11. Hanoteau A, Henin C, Moser M. L’immunothérapie au service de la chimiothérapie, de nouvelles avancées. Med Sci (Paris) 2016 ; 32 : 353–361. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. https://en.wikipedia.org/wiki/National_Institute_for_Health_and_Care_Excellence. [Google Scholar]
  13. Jordan B. « Explosion des cancers » : retour aux chiffres. Med Sci (Paris) 2016 ; 32 : 1139–1144. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Rolink G. The pharmaceutical industry has a large amount of control over the field of oncology. https://promarket.org/pharmaceutical-industry-large-amount-control-field-oncology/. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.